Mary Anne Heino named president of Angelini Labopharm
This article was originally published in Scrip
Executive Summary
Mary Anne Heino has been appointed president of Angelini Labopharm. She was formerly senior vice-president of sales and marketing for Labopharm and president of the company's wholly owned subsidiary, Labopharm USA. Succeeding Ms Heino as president of Labopharm USA is Dr Jeffrey Dayno, Labopharm's chief medical officer. Ms Heino joined Labopharm in 2007, having held executive positions at Centocor (Johnson & Johnson), including vice-president of strategic planning and competitive intelligence, and vice-president of sales. The Angelini Labopharm joint venture was formed last year for the US commercialisation of Oleptro, a once-daily formulation of the antidepressant trazodone hydrochloride approved by the US FDA for the symptomatic relief of major depressive disorder in adults.